Related by context. All words. (Click for frequent words.) 78 selective antagonist 76 peripherally acting 76 PDE4 inhibitor 76 sodium glucose cotransporter 76 protein tyrosine phosphatase 1B 76 reversible inhibitor 75 oral prodrug 75 orally administered inhibitor 75 receptor partial agonist 74 non nucleoside inhibitor 74 receptor tyrosine kinase inhibitor 74 selectively inhibits 74 TNF Tumor Necrosis Factor 74 ADP receptor antagonist 74 Squalamine 74 selective kinase inhibitor 73 Kinase Inhibitor 73 sunitinib Sutent ® 73 polymerase inhibitor 73 Angiotensin Converting Enzyme 73 Panzem R 73 #HT# 73 Orally administered 73 mitogen activated ERK kinase 73 Zorbtive TM 73 potently inhibits 73 pan HDAC inhibitor 72 orally bioavailable 72 MTP inhibitor 72 Trodusquemine 72 potently inhibit 72 anti amnesic 72 dopamine D2 72 PEGylated anti 72 fosbretabulin 72 2 methoxyestradiol 72 investigational humanized monoclonal antibody 72 AAG geldanamycin analog 72 combines bupropion 72 cyclin dependent kinase inhibitor 72 Hsp# Inhibitor 72 partial agonist 72 PNP inhibitor 72 selective inhibitor 72 intranasal formulation 72 selective agonist 72 Initiates Phase II 72 multi kinase inhibitor 72 selective modulator 72 liposomal formulation 72 5 HT6 receptor 72 Tezampanel 72 opioid receptor antagonist 72 nucleoside analog 72 generation Hsp# inhibitor 72 Pathway Inhibitor 71 CDK inhibitor 71 CYP#A# CYP#D# 71 selective inhibition 71 5 HT2A inverse 71 anticancer compound 71 Initiates Phase III 71 Talabostat 71 histone deacetylase inhibitor 71 GW# [003] 71 neuroprotective properties 71 small molecule tyrosine 71 CYT# potent vascular disrupting 71 HSP# inhibitor 71 proteasome inhibitor 71 Presents Preclinical Data 71 Receptor Agonist 71 Silodosin 71 ENMD # 71 Bosutinib 71 hyaluronidase enzyme 71 chimeric monoclonal antibody 71 PEGylated Fab fragment 71 investigational oral inhibitor 71 pan histone deacetylase 71 THR beta agonist 71 beta 1a 71 pathophysiological effects 71 AKT inhibitor 71 R Saizen R 71 novel histone deacetylase 71 NS#/#A protease 71 selectively inhibited 71 imatinib Gleevec ® 71 mTOR mammalian target 71 Factor Receptor 71 erlotinib Tarceva ® 71 vinca alkaloid 71 MAGE A3 ASCI 71 D aspartate NMDA receptor 71 P2Y 71 reversible inhibitors 71 selective estrogen receptor modulator 71 long acting muscarinic 71 Initiates Clinical 71 HCV protease 71 Kuvan sapropterin dihydrochloride 71 5 HT2A serotonin 70 Enzastaurin 70 IMiDs ® 70 Dasatinib 70 ARRY # 70 vapreotide acetate 70 IAP inhibitor 70 Marqibo TM 70 Tyrima 70 reuptake inhibitor 70 small molecule Hedgehog 70 PRT# 70 Epothilones 70 Vidofludimus 70 mertansine 70 SERMs 70 Archexin 70 small molecule glucokinase 70 Liposomal 70 Bafetinib 70 antagonist LAMA 70 inhaled formulation 70 Orally Active 70 potent inhibitor 70 orally dosed 70 Mg Usa 70 Personalized Immunotherapy 70 hypoxia activated prodrug 70 kidney urologic 70 ALN HPN 70 potent antiproliferative 70 multikinase inhibitor 70 FDA APPROVES 70 P#X# antagonist 70 PI3K/mTOR 70 modulator SERM 70 PTP 1B 70 Blinatumomab 70 DNA intercalator 70 proprietary polysaccharide 70 targeting CD# 70 HCV RNA polymerase 70 PSN# [002] 70 Initiates Enrollment 70 HER1 70 Serostim ® 70 indinavir Crixivan 70 peripherally restricted 70 highly selective endothelin 70 selective inverse agonist 70 XL# XL# 70 phosphate S1P 70 5 HT3 antagonist 70 topoisomerase II inhibitor 70 virus HCV protease inhibitor 70 SGLT2 inhibitor 69 Completes Patient Enrollment 69 PKC# 69 thromboxane A2 69 oral dihydropyrimidine dehydrogenase DPD 69 gamma secretase inhibitor 69 thalidomide Thalomid 69 mGluR2 NAM 69 selective adenosine 69 Intravenous Human 69 5 HT2C serotonin 69 mGluR5 negative 69 HMG CoA reductase inhibitors 69 LymphoStat B belimumab 69 Trodusquemine MSI 69 MEK inhibitor 69 vascular disrupting agent 69 neurokinin 1 69 generation purine nucleoside 69 novel VDA molecule 69 itraconazole Sporanox 69 5 HT1A 69 novel peptide 69 novel immunomodulatory 69 type glutamate receptor 69 cathepsin K inhibitor 69 immunomodulating 69 histone deacetylase HDAC inhibitor 69 peptidic compound 69 Drug Candidate 69 lexidronam injection 69 mGluR2 positive 69 Vidaza R 69 dasatinib Sprycel ® 69 Cytochrome P# 69 Phase #b/#a clinical 69 prostanoid 69 irreversible inhibitor 69 hormone LHRH antagonist 69 Deforolimus 69 Aurora Kinase 69 Romidepsin 69 methylnaltrexone bromide 69 hypoxia inducible factor 69 Mg Uk 69 AMPA kainate 69 XL# anticancer compounds 69 Anti Tumor 69 Denufosol 69 targeted antifolate 69 IMiDs R 69 sulindac 69 PI3K/Akt pathway inhibitor 69 liposome encapsulated 69 mecamylamine 69 stable nucleic acid 69 cMET 69 CCR2 69 platform HDL Mimetic 69 Luteinizing Hormone Releasing Hormone 69 evaluating tivozanib 69 Maribavir 69 5HT 69 Saizen ® 69 Granulocyte Colony Stimulating Factor 69 small molecule inhibitor 69 targeted radiotherapeutic 69 aripiprazole Abilify 69 serotonin norepinephrine reuptake inhibitor 69 Presents Preclinical 69 systemic RNAi therapeutic 69 sulfonylhydrazine class 69 norepinephrine reuptake inhibitor 69 angiogenesis inhibitor 69 radiation sensitizer 69 Onconase 69 dihydrochloride 69 Trandolapril 69 IL# PE#QQR 69 immune modulating 69 Parathyroid Hormone 69 N methyl 69 Phase 2b Clinical Trial 69 MEK inhibitors 69 tubulin inhibitor 69 oral dual endothelin 69 Bicalutamide 68 protein kinase inhibitor 68 receptor agonist 68 mediated inhibition 68 cetuximab Erbitux R 68 epothilones 68 humanized anti 68 potently inhibited 68 signal transduction inhibitor 68 estrogen receptor antagonist 68 CCX# 68 Zoraxel TM 68 Xeloda ® 68 Alfacell proprietary ribonuclease 68 Investigational Oral 68 CCR9 antagonist 68 dasatinib Sprycel 68 humanized monoclonal 68 Files IND 68 * olmesartan medoxomil 68 dual PPAR peroxisome 68 developing Bicifadine serotonin 68 Novel Oral 68 product candidate Lpathomab 68 Cyclooxygenase Inhibiting Nitric Oxide 68 Colesevelam 68 octreotide acetate 68 Calcitonin 68 Xanafide 68 accumulate preferentially 68 Tumor necrosis factor 68 Akt inhibitor 68 TNF alpha selectively neutralizing 68 Receives Orphan Drug Designation 68 Omacetaxine 68 histone deacetylase 68 alkylating agent 68 plasma kallikrein inhibitor 68 Achieves Primary Endpoint 68 orally bioavailable mimics 68 Factor VIIa 68 acyclovir Lauriad R 68 selective orally bioavailable 68 EGFR HER2 68 NNRs 68 Inhalation Aerosol 68 Fc fusion protein 68 Interferon alpha 68 SAR# [002] 68 selective A2A adenosine receptor 68 selective serotonin 2C receptor 68 Janus kinase 68 mu opioid receptor antagonist 68 lamotrigine Lamictal 68 Selective Inhibitor 68 JAK2 inhibitor 68 AEG# 68 GVAX ® 68 Meets Primary Endpoint 68 ABLYNX 68 vaccine GRNVAC1 68 Pegloticase 68 PDX pralatrexate 68 Panzem NCD 68 phosphatidylinositol 3 68 Iloperidone 68 sphingosine 1 68 non thiazolidinedione TZD 68 nilotinib Tasigna 68 Phase 2a Clinical Trial 68 Pharmacokinetics PK 68 Randomized Double blind 68 anionic backbone 68 Sphingosine 1 68 Protelos R 68 SinuNase ™ 68 acetonide FA 68 serotonin reuptake inhibitor 68 Voreloxin 68 insulin sensitizing 68 TRX1 68 Aflibercept 68 small molecule defensin 68 endothelin receptor 68 anti angiogenic agent 68 inhibitor SNRI 68 PHX# 68 adenosine A2A 68 adrenoceptor agonist 68 PDE4 68 HGS ETR2 68 thetreatment 68 chemokine receptor 68 Pimavanserin 68 NR2B selective 68 Bucindolol 68 5 HT4 receptor 68 Successfully Completes Phase 68 microtubule inhibitor 68 peptibody 68 Ridaforolimus 68 Recombinant Human 68 Sapacitabine 68 JAK2 Inhibitor 68 Tyrosine Kinase Inhibitor 68 HCV NS5B polymerase 68 Zoraxel 68 pro apoptotic 68 Initiates Phase 2b 68 oral ghrelin agonist 68 TLK# 68 2A receptor agonist 68 Cathepsin S 68 pralatrexate injection folate analogue 68 5 HT1A receptor 68 DNA demethylating agent 68 cromolyn sodium 68 polyglutamate 68 antimitotic 68 antisense inhibitors 68 Initiates Clinical Trial 68 somatostatin analog 68 agonistic human 68 MET VEGFR2 68 Aliskiren 68 receptor modulator 68 Dapagliflozin 68 peroxisome proliferator activated 68 Locked Nucleic Acid LNA 68 Seliciclib 68 M2 subunit 67 ALN TTR 67 topically applied SEPA 67 tubulin binding 67 rHuPH# recombinant human 67 MEK Inhibitor 67 potent anticancer 67 sapropterin dihydrochloride 67 CYC# 67 antibody MAb 67 Genasense ® oblimersen 67 Pruvel TM 67 small molecule chemotherapeutic 67 agent VDA 67 Upregulation 67 selective androgen receptor modulator 67 class anticancer quinolone 67 candidate deforolimus 67 Preclinical studies suggest 67 IMiD 67 receptor antagonist 67 matrix metalloproteases 67 GMX# 67 allosteric modulator NAM 67 PRTX 67 novel prodrug 67 c Raf kinase 67 Febuxostat 67 inhalation powder 67 TO AVOID PREGNANCY WHILE 67 SPL# Gel vaginal microbicide 67 MKC# MT 67 Imatinib mesylate 67 inverse agonist 67 Naproxcinod 67 inhibit oxidative stress 67 Bevirimat 67 humanized monoclonal antibody 67 vascular disrupting agents 67 Carfilzomib 67 polysaccharide polymer 67 selectively inhibit 67 PEG SN# 67 iobenguane 67 Nanobody ® 67 aurora kinase 67 FGFR 67 novel orally administered 67 metaglidasen 67 LPA1 receptor 67 Ad5FGF 4 67 Tigecycline 67 PEGylated interferon 67 Oral Formulation 67 N acetylgalactosamine 6 67 Protein Kinase C 67 receptor blocker 67 Vidaza azacitidine 67 5 HT2C 67 small molecule thrombopoietin 67 sorafenib tablets 67 Dabigatran etexilate 67 topical gel formulation 67 inhibits protein synthesis 67 Horizant ™ 67 CORT # 67 HDAC Inhibitor 67 antisense inhibitor 67 ATL# [002] 67 DU #b 67 Tarceva TM 67 Anti VEGF 67 AVAPRO 67 ZOLINZA 67 NS5B polymerase 67 Coadministration 67 SGLT2 67 reslizumab 67 PRN FDA Approves 67 #beta HSD1 67 leukotriene pathway 67 DNA methyltransferase inhibitors 67 P#Y# [002] 67 rivastigmine Exelon 67 histamine dihydrochloride 67 SARMs 67 vidofludimus 67 demonstrated antitumor activity 67 HGS# 67 #mg/#mg 67 IAP inhibitors 67 p# MAP kinase inhibitor 67 secretory phospholipase A2 67 NMDA antagonist 67 JAK inhibitor 67 Safinamide 67 somatostatin 67 immunostimulatory 67 oral nucleoside analogue 67 peptidomimetic 67 receptor PPAR 67 Prolongs Survival 67 tyrosine kinase inhibitor 67 albiglutide 67 Varespladib 67 oral Janus kinase 67 Aurora kinase 67 Omacetaxine mepesuccinate 67 anticancer agent 67 Cannabinor 67 Factor VEGF 67 SYN# 67 TLR8 agonist 67 cytoprotective 67 Methylnaltrexone 67 insulin sensitizer 67 dihydrofolate reductase 67 hyperphosphorylation 67 glucagon receptor 67 Long acting beta2 67 siRNA binds 67 vivo validation 67 Reports Preclinical Data 67 selective adhesion molecule 67 Pazopanib 67 RNA antagonist 67 acadesine 67 davalintide 67 Antitumor 67 selective estrogen receptor 67 DG# compounds targeting 67 volociximab 67 Temsirolimus 67 selective immunoproteasome inhibitor 67 Darapladib 67 specific protein tyrosine 67 ALN PCS 67 ropinirole Requip 67 Ropinirole 67 telomerase therapeutic 67 antiapoptotic 67 converting enzyme 67 LPA1 67 XP# XP# 67 tiapamil 67 receptor inhibitor 67 triggers apoptosis programmed 67 receptor modulators 67 Valproic acid 67 rxRNA 67 Liprotamase 67 novel synthetic peptide 67 protein secreted 67 Phase IIb Trial 67 5 HT2A receptor 67 anti secretory 67 Pafuramidine 67 Elvitegravir 67 Epratuzumab 67 positive allosteric modulator 67 serine threonine 67 HCV polymerase 67 Epidermal Growth Factor Receptor 67 biased ligand 67 antidiabetic drug 67 Angiolix 67 sorafenib Nexavar 67 Oral Fingolimod 67 calcitonin gene related 67 PF # [002] 67 immunomodulator 67 YONDELIS 67 FOLOTYN ® 67 Disease IBD 67 thrombin receptor 67 delta opioid receptor 67 humanized therapeutic 67 non porcine pancreatic 67 PDE# 67 oral beclomethasone dipropionate 67 HCD# [002] 67 mineralocorticoid 67 dexlansoprazole 67 Angiocept 67 BUPHENYL R 67 sublingual formulation 67 ® lenalidomide 67 Lubiprostone 67 Kahalalide F 67 HCV polymerase inhibitors 67 Aurora kinase inhibitor 67 adecatumumab MT# 67 Initiate Phase 67 arginine vasopressin AVP 67 p# mitogen activated 67 Afatinib 67 therapeutically inactive prodrug 67 cortisol synthesis 67 CCR9 67 Darinaparsin 67 Ozarelix 66 5 FU leucovorin 66 tenofovir Viread 66 carbohydrate polymer 66 Friedreich Ataxia FRDA 66 phase III isavuconazole 66 selectively inhibiting 66 triciribine phosphate monohydrate 66 TLR9 agonist 66 candesartan cilexetil 66 alvespimycin 66 agonists antagonists 66 Granted Orphan Drug 66 Romiplostim 66 inhibitor PPI 66 selective phosphodiesterase 66 mediated apoptosis 66 advanced metastatic renal 66 CCR1 66 JAK1 66 LAB CGRP 66 gastro intestinal inflammation 66 oncolytic virus therapies 66 Angiotensin 66 PORxin TM 66 Elagolix 66 compound perifosine 66 CYP#A# isoenzyme 66 angiotensin receptor blocker ARB 66 PYY #-# 66 Presents Positive 66 immune stimulatory 66 lanreotide 66 Aclidinium 66 TLR7 agonist 66 dextromethorphan quinidine 66 BXT # 66 investigational pharmacologically unique 66 MET RET 66 integrin inhibitor 66 oral picoplatin 66 P#Y# [001] 66 RON Notch 66 IgG1 monoclonal antibody 66 #HT#A 66 Gonal f ® 66 direct thrombin inhibitors 66 somatostatin analogue 66 investigational oral 66 oral proteasome inhibitor 66 aurora kinase inhibitor 66 Isavuconazole 66 Pyridorin 66 mTOR inhibitor 66 neuronal nicotinic receptors NNRs 66 Vascular Disrupting Agent 66 hypereosinophilic syndrome 66 depsipeptide 66 Agonist MABA program 66 MGd 66 Hsp# chaperone system 66 potent vasodilator 66 cleavable linker 66 Angiolix R 66 Receptors GPCRs 66 BMS # 66 Phase 2b Trial 66 non nucleoside 66 HGS ETR1 mapatumumab 66 Saizen R 66 5 lipoxygenase activating 66 rusalatide acetate 66 Submits NDA 66 OTCBB PYTO 66 systemically administered 66 immunoconjugate 66 forodesine 66 Myolimus 66 INSPIRE Trial Phase III 66 hypoxia selective 66 Oral Spray 66 adult mesenchymal stem 66 Retinoic Acid 66 mGluR5 NAM 66 Begins Dosing 66 Monoclonal Antibody 66 molecular imaging radiopharmaceutical 66 Replacement Therapy 66 COX Inhibiting Nitric Oxide 66 neuroprotectant 66 small molecule activator 66 Empatic TM 66 therapeutic monoclonal antibody 66 inhibitor RG# 66 AZD# ARRY # 66 glucokinase activator 66 nucleotide analog 66 small molecule modulators 66 delivers fluocinolone acetonide FA 66 imipramine Tofranil 66 VEGFR2 inhibitor 66 acetylcholine receptor 66 Serdaxin ® 66 diarrhea predominant irritable 66 deacetylase 66 Bremelanotide 66 Tanespimycin 66 alpha 2A 66 inhibitor rofecoxib 66 antiproliferative effects 66 ergot derivatives 66 Small Molecule 66 ThermoDox ® clinical 66 monoclonal antibody conjugated 66 Qutenza TM 66 nicotinic acetylcholine receptor 66 RhuDex ® 66 Hsp# inhibitors 66 NS5b 66 Aptamer 66 metabolic inhibitor 66 mGluR4 66 ALK inhibitor 66 RELOVAIR ™ 66 immune modulatory 66 citicoline 66 Locked Nucleic Acid 66 mTOR kinase 66 lenalidomide Revlimid R 66 FOLFOX6 chemotherapy regimen 66 cysteamine bitartrate 66 binds selectively 66 IMiDs ® compound 66 Triapine R 66 docetaxel Taxotere ® 66 Curaxin CBLC# 66 mitotic kinesin 66 anti fibrotic 66 Muraglitazar 66 glutathione peroxidase 66 Immunomodulatory 66 Antiarrhythmic 66 Hypoxia Inducible Factor 66 OMP #M# 66 Monopril 66 antisense oligonucleotide 66 methyl D aspartate 66 TRANSDUR ® 66 Aplidin 66 synthetic siRNA 66 potent topoisomerase II 66 R lenalidomide 66 REP# 66 RAS MAPK pathway 66 bevacizumab Avastin R 66 OMNARIS HFA 66 Veronate R 66 mild vasodilator 66 CRIXIVAN 66 Lenocta TM 66 small molecule agonists 66 p# inhibitor 66 kinase inhibitor 66 indibulin 66 Crofelemer budesonide foam 66 Pertuzumab 66 substrates inhibitors 66 HCV protease inhibitor 66 Receptor Antagonist 66 brain penetrant 66 ZD# [001] 66 reverse transcriptase inhibitors 66 brivanib 66 abacavir sulfate lamivudine 66 proteasome inhibitors 66 Neulasta R 66 essential thrombocythemia ET 66 Ostabolin C TM 66 Ovitrelle R Serostim 66 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 66 BAL# [001] 66 refractory chronic lymphocytic 66 TAFA# 66 2 inhibitor CYT# 66 HQK 66 Ganciclovir 66 treat male hypogonadism 66 Protease Inhibitor 66 naturally occurring molecule 66 vesicular monoamine transporter 66 initiated Phase Ib 66 formerly LymphoStat B 66 LY# [003] 66 MEK ERK 66 candidate DB# 66 Selective inhibition 66 Itraconazole 66 chronic eosinophilic leukemia 66 R memantine HCl 66 Demonstrates Efficacy 66 Kinoid 66 erythropoietic 66 Atripla combines 66 Gel repository corticotropin injection 66 GSK '# 66 immunomodulatory properties 66 Tasimelteon 66 Preclinical Data 66 Thiarabine 66 anti CD3 66 cytochrome p# 66 alefacept 66 Avanafil 66 Demonstrates Significant 66 Initiate Clinical Trial 66 Cancidas 66 lucinactant 66 Elesclomol 66 pregabalin Lyrica 66 humanised monoclonal antibody 66 esomeprazole Nexium 66 Tumour Vascular Disrupting Agent 66 FUSILEV enhances 66 tubulin polymerization 66 NOX E# 66 p# alpha [001] 66 Fulvestrant 66 nasal spray formulation 66 PGL# 66 developing Zerenex ferric 66 M# rationally 66 RNAi therapeutic targeting 66 Sandimmune 66 nucleotide analogue 66 levetiracetam Keppra 66 Anidulafungin 66 Opterone R 66 Serostim R 66 MOVIPREP R 66 Zybrestat 66 Transdermal Delivery 66 Bezielle 66 Talactoferrin 66 lapatinib Tykerb 66 neuronal nitric oxide synthase 66 selective A1 adenosine 66 Tesetaxel 66 receptor activator 66 adenosine injection 66 acid GABA 66 Vinorelbine 66 BRILINTA 66 activin receptor type 66 histone deacetylase HDAC 66 MCSP respectively 66 Immunotherapeutic 66 varespladib 66 ocular formulation 66 Adenoscan R 66 HFA MDI 66 GAD# 66 Cleviprex TM clevidipine 66 inhibitor COX 66 TRO# 66 brand ciclesonide HFA 66 Initiates Dosing 65 colony stimulating factor 65 aberrantly activated 65 Palifosfamide 65 Investigational Compound 65 factor receptor FGFR 65 Monoclonal antibody 65 Vidaza ® 65 Darusentan 65 nitric oxide donating 65 elastase 65 Belerofon 65 Known generically 65 recombinant fusion 65 alpha#beta# 65 5alpha reductase 65 Ziprasidone 65 terfenadine 65 Biolimus A9 65 Phase III Clinical Trial 65 CD# CEA 65 NMDA receptor antagonist 65 generation antisense inhibitor 65 delta gamma agonist 65 5 HT4 65 METOZOLV TM ODT metoclopramide 65 Shai Novik President 65 HIV integrase inhibitor 65 Xyfid TM 65 myelofibrosis polycythemia vera 65 peptide CGRP 65 Peginterferon alfa 2b 65 thiazolidinedione TZD 65 BAL# [002] 65 GLYX 65 SUTENT ® 65 polymerase inhibitors 65 targetters 65 Thiovir 65 AT1R 65 oral salmon calcitonin 65 Prodrug 65 Ambrisentan 65 5 hydroxytryptamine 65 Peptide YY 65 Phase Ib Clinical Trial 65 Nitazoxanide 65 TRPV1 agonist 65 Saquinavir 65 Histone deacetylase 65 Allosteric 65 Cotara ® 65 Lispro 65 flavopiridol 65 TAKSTA 65 Initiates Phase 65 Multiple Ascending Dose 65 delivery polymer matrix 65 histone deacetylase HDAC inhibitors 65 synthetic retinoid 65 Paxil paroxetine 65 immunotoxin 65 TPI ASM8 65 ghrelin receptor 65 hyperphenylalaninemia HPA due 65 XYOTAX TM 65 Receptor Antagonists 65 Ticagrelor 65 Nexavar ® 65 sulodexide 65 MKC# 65 Doripenem 65 Formoterol 65 Combination REOLYSIN R 65 ziprasidone Geodon 65 Pterostilbene 65 Commences Phase 65 visilizumab 65 non peptidic protease 65 TNFalpha 65 oxidative stress inducer 65 pharmacologically active isomer 65 beta2 agonist 65 tumor xenograft models 65 targets Galectin receptors 65 mitogen activated protein kinase 65 proliferator activated receptor 65 Panzem R NCD 65 Factor Xa inhibitor 65 metformin sulfonylurea 65 gets USFDA nod 65 LymphoStat B TM 65 Glatiramer acetate 65 Ceflatonin R 65 familial amyloidotic polyneuropathy FAP 65 Tumor Necrosis Factor 65 geldanamycin 65 Beta catenin pathway 65 induces apoptosis 65 5 Fluorouracil 65 DFMO 65 LibiGel ® 65 uricase 65 HDACi 65 NS3 protease 65 urate oxidase 65 telomerase inhibitor drug 65 Sphingomab 65 orally inhaled 65 Pivotal Phase III 65 Indomethacin 65 huC# DM4 65 CGRP 65 Azacitidine 65 Fondaparinux 65 receptor antagonists 65 muscarinic 65 phosphoinositide 3 65 Forodesine 65 TRAIL R2 65 enzyme inhibitor 65 luteinizing hormone releasing 65 BCG refractory carcinoma 65 R bisoprolol Euthyrox 65 pathway inhibitor 65 Solulin 65 PROSTASCINT R 65 Cloretazine ® 65 IMA# 65 specific lectin receptors 65 Therapeutic Competitors Companies 65 CB2 receptor 65 Mycophenolate Mofetil 65 adrenoceptor 65 PPAR peroxisome proliferator activated 65 MKC# MKC# PP 65 Completes Enrollment 65 YONDELIS R 65 CYP #C# 65 See CLINICAL PHARMACOLOGY 65 Alagebrium 65 Initiates Clinical Trials 65 azoles 65 alpha agonists 65 EVIZON TM 65 Nanobody 65 R#/MEM # 65 alpha#beta# integrin 65 Kosan dependence 65 IMPDH inhibitor 65 defensin mimetic antibiotic 65 alpha folate receptor 65 Elotuzumab 65 Receives Approvable Letter 65 Novolimus 65 HepDirect prodrug 65 muscarinic antagonist 65 potent inhibition 65 CDK cyclin dependent 65 selective inhibitors 65 Phase 1b clinical trials